[Prevention of vascular complications after cerebral ischemia of arterial origin. European Stroke and Australian Stroke Prevention in Reversible Ischemia Trial (ESPRIT): moderated coagulation, aspirin-dipyridamole combination or aspirin alone?].
De Schryver
E L
EL
Trial Bureau Neurologie, Academisch Ziekenhuis Utrecht.
Gorter
J W
JW
Algra
A
A
van Gijn
J
J
D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D004176:Dipyridamole / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D004176:Dipyridamole; D001241:Aspirin
Prévention des complications vasculaires après ischémie cérébrale d'origine artérielle. Etude ESPRIT: anticoagulation modérée, association aspirine-dipyridamole ou aspirine seule?